M40403

DRUG2 trials

Sponsors

MetaPhore Pharmaceuticals

Conditions

CancerIL-2 Induced HypotensionPain

Phase 1

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

SuspendedNCT00033956

MetaPhore PharmaceuticalsIL-2 Induced Hypotension

Start: 2001-12-31Target: 48Updated: 2005-06-24

Phase 2

Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain

TerminatedNCT00101621

MetaPhore PharmaceuticalsCancer, Pain

Start: 2004-08-31End: 2005-08-31Target: 24Updated: 2006-02-09